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ABSTRACT
Objective Menthol is an important additive in most
tobacco products and is an identifying characteristic of
many brands. We assessed tobacco companies’
research on direct disease-inducing effects of menthol
and menthol cigarettes.
Methods A search was conducted among documents
included in the Legacy Tobacco Documents Library.
Relevant documents addressed subject areas such as
pharmacology, short-term and long-term effects and
biomarkers of smoking exposure.
Results The documents contain little internal industry
research on the disease-inducing effects of menthol.
Most information in the tobacco industry documents are
reviews of the published biomedical literature, from
which the companies concluded that menthol did not
have any direct disease-inducing effects. Evidence that
contradicted this conclusion was downplayed. Except for
one study, there was no evidence of the companies
following up on positive ﬁndings in the literature with
their own studies. In one case, results were presented at
a public scientiﬁc meeting concluding that ‘There were
no effects from addition of menthol to test or reference
cigarettes’, when a company’s internal pathology
analysis contradicted this statement.
Conclusion The available industry documents suggest
that tobacco companies conducted little research on the
potential disease-inducing effects of menthol and did not
pursue studies that suggested adverse effects.
INTRODUCTION
Though menthol has been used in foods and
confections for many years, this does not neces-
sarily mean that its addition to cigarettes (which
are burned and then inhaled) is innocuous.
Although a 2010 published paper from the Lorillard
Tobacco Company states that ‘menthol employed
as a cigarette tobacco ﬂavouring ingredient does not
meaningfully affect the inherent toxicity of ciga-
rette smoke or the human risks that attend
smoking’,
1 this conclusion is not supported by all
the scientiﬁc literature. In a 2010 commentary,
Hammons noted that although a limited number of
epidemiological studies that examined the relation
between menthol cigarette smoking and disease
risk found no association with increased deaths
from cancer, coronary heart disease or other
cardiovascular diseases, their limitations (including
the difﬁculty in classifying subjects as exclusively
menthol or non-menthol smokers for a long enough
time or large enough sample size to detect an
increment in risk above the large risk caused by
smoking in general) caution against treating these
results as conclusive.
2 The presence of menthol and
alcohol increases the ﬂux of tobacco carcinogens
across porcine oesophagus
3 and menthol enhances
the penetration of nicotine through porcine buccal
mucosa
4 in in vitro systems. Menthol might also
inhibit the detoxiﬁcation of the potent carcinogen
NNAL.
5 In addition, menthol’s interaction with
biomarkers of smoking exposure such as cotinine
and carbon monoxide remains unclear: published
studies have shown contradictory results,
5e9 with
one of these studies
7 published by the Altria Client
Services Inc, part of Altria/Philip Morris.
Although menthol is a Food and Drug Adminis-
tration (FDA) approved food additive, the FDA is
now evaluating menthol as a cigarette additive.
This paper summarises studies that were either
conducted or supported by tobacco companies
concerning the direct disease-inducing effects of
menthol.
METHODS
A search was conducted among the tobacco
industry documents in the University of California,
San Francisco Legacy Tobacco Documents Library
(LTDL), which contains more than 11 million
documents created by major tobacco companies
related to theiradvertising,manufacturing,marketing,
sales and scientiﬁc research activities,
10 as described
in detail in this supplement by Anderson’s paper on
research methodology.
11 Based on the questions
posed by the FDA, initial keyword searches
combined terms related to menthol, adverse effects,
carcinogen, pharmacokinetics, cotinine, carbox-
yhaemoglobin. This initial set of keywords resulted
in the development of further search terms and
combinations of keywords (eg, biomarker, perme-
ation, conjugation). Relevant documents addressed
the pharmacology of menthol, short-term and long-
term effects of menthol, role of menthol on disease
risk and menthol’s effects on biomarkers of smoking
exposure. A ﬁnal collection of 209 documents was
deemed relevant to this study. Nineteen documents
that provided illustrative, detailed or exemplary
information supporting these themes are cited in
this paper.
RESULTS
Pharmacokinetics of menthol
Internal tobacco company research
In the early 1970s, the British American Tobacco
(BAT) Company commissioned a conﬁdential
literature survey by the British Industrial Biological
Research Association (BIBRA) that established the
paucity of deﬁnitive data on the pharmacody-
namics and pharmacokinetics of menthol following
ingestion and inhalation in either experimental
animals or humans.
12 During that time (1974), the
World Health Organization was discussing what
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Research paperwould be an acceptable maximum daily intake for orally
ingested menthol.
12 In response, in 1975, BATworked to develop
analytical chemical methods to detect menthol in blood
samples, including preliminary studies using data collected from
two middle-aged BATscientists who switched from their regular
cigarettes to mentholated cigarettes and also ingested menthol
orally.
12 The study found blood levels of menthol below 10 ppb
(parts per billion) in all but one experiment that involved only
one of the subjects smoking 32 cigarettes in an 8-hour period,
where 40 ppb of menthol was measured.
12
In 1976, the contract research organisation Life Science
Research delivered a ‘conﬁdential’ report to the BAT’s Group
Research & Development Centre summarising animal experi-
ments to determine absorption and pharmacokinetics of orally
administered menthol.
13 Four protocols of oral administration of
menthol to rats were conducted, with subsequent collection of
blood and urine samples. In one of these experiments, in which
224 rats were used, adipose and liver tissue samples were taken
from a subsample of the rats. A ﬁfth experiment was conducted
using one male dog to examine for possible species variation in
absorption and elimination of menthol. Free and conjugated
menthol (glucuronide, which the body produces by reacting
menthol with glucuronic acid to facilitate excretion) were
measured. Menthol was found to be poorly absorbed after oral
administration in both species (less than 2% of the oral dose was
recovered in the urine of rats over the ﬁrst 48 hours), and to be
excreted mostly as glucuronide (conjugated menthol) in urine.
Liver samples taken 8 weeks after the beginning of a daily oral
administration of menthol showed an increase in the activity of
hepatic UDP-glucuronyl transferase that seemed to be dose-
dependent, suggesting that menthol was metabolised by the
liver and that this was the enzyme that conjugates menthol.
Menthol was not found in any of the samples of adipose tissue
analysed.
13
A second Life Science Research report delivered in 1976
described ﬁve protocols using rats, guinea pigs, mice and
hamsters.
14 Of these ﬁve experiments, two rats were used in the
one with the smaller sample size, while groups of 24 mice,
hamsters and guinea pigs were used for the experiment with the
biggest sample size. In all cases, radiolabelled menthol was
administered by intraperitoneal injection. Maximum average
blood levels of radioactivity were observed within 2 hours in all
four species. Menthol was excreted mostly as glucuronide in
urine, with some excretion through faeces.
14
A 1978 report from the BAT’s Group Research and Develop-
ment Center
15 described two studies performed using human
subjects (three in one study and ﬁve in the other). Participants
were told to smoke mentholated cigarettes during the day. Urine
samples were collected in both studies before and after the
smoking period and blood sample were taken in one study.
When comparing the pre-smoking and post-smoking blood
samples, no increase in the levels of free menthol were found
after smoking up to 21 cigarettes in an 8-hour period Excretion
rate was maximal at the end of the smoking period, with
80e90% of the menthol being eliminated during the smoking
period or within 4 hours post-exposure.
15
Pyrolysis of menthol
Study published in the open literature
In 1968, Nature published a paper (by Schmeltz and Schlotz-
hauer, from the US Department of Agriculture) reporting that
the pyrolysis of menthol at 8608C produced benzo(a)pyrene,
a mutagen and carcinogen.
16 In 1970, Jenkins et al from Philip
Morris’s Research Center published a paper
17 18 in Beitraege zur
Tabakforschung (Contributions to Tobacco Research, which the
German Cigarette Manufacturers Association founded in
1961
19) presenting an analysis of menthol’s smoke distribution
and pyrolytic composition. They used radiolabelled
14C-menthol
in machine-smoked cigarettes and reported that the mainstream
smoke contained 28.9% of the total activity, sidestream smoke
contained 44.3% and the butt contained 26.9%. They reported
that pyrolysis products of menthol in the mainstream smoke
constituted only 0.4% of the total mainstream activity and that
the major
14C-menthol smoke product in the mainstream smoke
was unchanged menthol (98.9%), concluding there was very
little, if any, pyrolysis and combustion of menthol during
pufﬁng of a cigarette. They noted that Schmeltz and Schlotz-
hauer had found that menthol pyrolysis at 6008C did not result
in the formation of benzo(a)pyrene. They also argued that
because the boiling point of menthol (2128C) was well below
6008C, very little menthol pyrolysis would be expected.
17 18
However, as Schmeltz and Schlotzhauer had noted,
16 the
burning temperature of cigarettes exceeds 8008C, information
also found in a 1966 American Tobacco Company conﬁdential
report.
20
Long-term and short-term studies on the effects of menthol
Document developed for external release
In 1963, the Liggett & Myers Tobacco Company prepared
a report for the Surgeon General’s Advisory Committee on
Smoking and Health reporting on long-term carcinogenicity
assays in mice and rabbits.
21 Using 100 female mice, smoke
condensates were applied to the back of the animals and the rate
of incidence and time of appearance of skin papillomas and
carcinomas were recorded (follow-up period: 24 months). The
incidence of tumours in mice painted with the condensate from
mentholated cigarettes was not signiﬁcantly different from that
observed with condensates from non-mentholated cigarettes.
21
Internal tobacco company research
In 1984e5, RJ Reynolds’ Sensory Evaluation Division prepared
a ‘secret’ review of the literature to be used in an internal RJ
Reynolds training programme entitled ‘Menthol and the design
of mentholated cigarettes’.
22 This material aimed to provide
a summary of the information researchers needed to develop
mentholated cigarettes mostly focused on details of how to
design mentholated cigarettes to control menthol delivery and
perception. The review did, however, include a summary of the
literature on health effects, which concluded that no long-term
studies (greater than 1 year) of the effects of menthol cigarettes
were found in the literature and that, while case reports in
humans had appeared, the lack of controls in these cases made
the results questionable, that ‘menthol is not carcinogenic, as
shown in studies by [the National Cancer Institute]’ and that
‘no detrimental effects of menthol were observed in short term
biological studies’.
22
In 1988, as part of its research to develop Premier cigarettes
23
(a new product that delivered nicotine by heating beads covered
with nicotine rather than burning tobacco) RJ Reynolds devel-
oped 90-day inhalation study (denoted TRD-ATS-017) to
‘compare toxicological responses produced by menthol and
non-menthol test [heated tobacco] and reference [burned
tobacco] cigarettes . [using] 12 groups each containing up to 35
Sprague-Dawley rats per sex. Three graded concentrations of
smoke from both sets [menthol and non-menthol] of test and
reference cigarettes will be used, and the comparisons of test
and reference will be made on the basis of the amounts of wet
total particulate matter (WTPM) presented to the animals’.
24
Tobacco Control 2011;20(Suppl 2):ii44eii48. doi:10.1136/tc.2010.041962 ii45
Research paperEndpoints included histopathology, plasma levels of nicotine and
cotinine, haematology, organ and body weights and measure-
ments of respiratory physiology. The results of this study were
to be kept conﬁdential inside RJ Reynolds; the protocol stated,
‘This study will not be listed as a regulated study and the results
are not intended to be submitted to any regulatory agency’.
24
In 1990, RJ Reynolds submitted an abstract for the Society
of Toxicology annual meeting, reporting the results of study
TRD-ATS-017, that stated ‘There were no effects from addition
of menthol to test or reference cigarettes’.
25 Later that same
year, however, the TRD-ATS-017 ﬁnal histopathological report,
prepared for internal RJ Reynolds’ use, concluded that ‘for the
reference [conventional] cigarette, the histopathological changes
noted in the upper airways of the menthol cigarette groups were
more severe than those noted in the non-menthol cigarette
groups’.
26 Four years later, in May 1994, RJ Reynolds dismissed
the results in an interofﬁce memorandum,
23 arguing that the
comparisons between the reference cigarettes were not valid
since the conﬁguration of the two cigarettes was different. The
same memo stated that ‘no comparisons across reference groups
were required in the study protocol and are also not germane to
the purpose of this study’.
23 But in August 1994, the RJ
Reynolds scientiﬁc and regulatory affairs team
27 questioned the
reasons for dismissing the results because:
This argument is made principally on the grounds that the two
cigarettes are in fact different with regard to distinct blend and
physical characteristics. However, given that the mentholated
conventional product utilized as a control in this study contained
more reconstituted tobacco sheet and more non-tobacco
ingredients, one would have predicted that it would have displayed
reduced activity relative to the Kentucky 1R4F [non-menthol]
reference cigarette. In short, study TRDATS-017 may have
understated the potential for menthol to produce adverse effects.
27
A‘PM conﬁdential’‘ Risk Assessment for Menthol’ prepared by
Philip Morris Product Integrity in 1999
28 provided a compre-
hensive review of the regulatory environment around menthol
and the state of the open literature. It remarked that most
studies using human subjects were case reports and that
conclusions were therefore anecdotal. It also concluded that,
considering the ubiquitous use of menthol, it was almost certain
that the presence of clinical symptoms in those cases (such as
a case of psychological disturbance caused by 3 years of nasal
application of an ‘over-the-counter’ medication that contained
menthol) were due to instances of extreme exposure.
28 The
review also contained results from a few unpublished PM
internal studies, including results from eye and skin irritation
studies. Results of the primary skin irritation test in rabbits
using showed no dermal irritation. When instilling microcap-
sules into the rabbit’s eye, slight conjunctival redness was
observed 1 hour after dosing, but later evaluations at 24, 48 and
72 hours post-treatment showed no irritation. The ﬁnal
conclusion was that menthol was non-irritating. Under the
same protocol, a second study of microcapsule instillations
produced a group average score of two (out of possible 110) at
24 hours and 48 hours after treatment and this response resolved
by 72 hours post-treatment, led to the conclusion that menthol
was minimally irritating to the rabbit eye.
28 The risk assessment
did note that that there was some evidence that menthol had
adverse health effects, but dismissed these studies on technical
grounds. For example:
Epidemiology presents conﬂicting data with respect to biological
effects from mentholated cigarette smoke in humans. African
American men have been reported to have a 60% higher lung cancer
incidence than the US white male population. Although the
number of cigarettes smoked per day is signiﬁcantly lower among
African Americans, they smoke cigarettes with higher tar content.
Fifty-ﬁve percent of African Americans smoke mentholated brands
of cigarettes. Some studies have reported increases in lung cancer
incidence in long-term mentholated cigarette smoking individuals
from different races, while other studies report menthol smoking is
not a strong risk factor for lung cancer. Although many hypotheses
have been advanced with respect to the possible mechanisms
associated with the reported lung cancer ‘increases’, these
hypotheses remain unproven. Confounding factors such as
socioeconomic status, access to health care, quality and usage of
care, smoking behavior, physiological changes from menthol
affecting smoking mechanics, and racial differences in levels and
activity of P450 enzymes have generally not been evaluated in this
context.
28
The conclusion of the report was that ‘There are no antici-
pated risks associated with the use of menthol in cigarettes at
the current application levels’.
28
In 2001, Philip Morris prepared an extensive review of regu-
latory issues related to menthol, together with an extensive
summary of the available scientiﬁc literature, including some
internal studies on smoke chemistry. (The intended audience for
this report is not clear.) This review reported the evidence of
adverse effects on pulmonary function in workers exposed to
menthol, epidemiological evidence linking smoking menthol
cigarettes with lung cancer in men and oesophageal cancer in
women, and that adding menthol increased the amount to
total particulate matter in the smoke, but downplayed these
results, concluding that ‘menthol has a low order of acute
toxicity and has been demonstrated to be non-carcinogenic and
non-teratogenic’.
29
Study published in the open literature
In 1999, RJ Reynolds published the results from a study
30 31 that
assessed psychophysiological (EEG and heart rate) and subjective
(such as mental alertness and anxiety/nervousness) effects of
smoking menthol versus non-menthol cigarettes smokers using
denicotinised cigarettes (to study the effects of menthol inde-
pendently of the effects of nicotine). Twenty-two volunteers (12
regular menthol smokers, 10 regular non-menthol smokers) were
recruited. Both type of smokers smoked two commercial deni-
cotinised cigarettes (which still contain low levels of nicotine):
menthol and non-menthol. Menthol smokers showed a greater
increase in heart rate following smoking either cigarette (around
5 bpm) than did non-menthol smokers (around 2 bpm), which
could indicate that menthol smokers were more sensitive to the
low levels of nicotine in the denicotinised cigarettes, implying
they could be more sensitive to the effects of nicotine itself.
Menthol smokers had a slower EEG alpha rhythm (9.35 Hz) than
non-menthol smokers (10.08 Hz) with the eyes closed, leading
to the conclusion that regular menthol smokers seemed to be
less aroused by menthol than regular non-menthol smokers.
30 31
The conclusion in the abstract of the draft manuscript located in
the industry documents was ‘We also report evidence that
menthol smokers may be chronically less aroused and more
sensitive to the effects of nicotine than non-menthol smokers’.
32
In the published paper, an additional conclusion was added to the
abstract: ‘We found little evidence that menthol in cigarettes has
central pharmacological effects’.
30 31
Menthol, nicotine, cotinine and carbon monoxide
Study published in the open literature
In 1997, Lorillard published an article in Food and Chemical
Toxicology
33 34 reporting the results of a study of two rats
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(21 rats per sex for reference and 15 per sex for menthol) for an
hour a day, 5 days a week, for 13 weeks. Within each group,
three different concentrations of target smoke were used
(200 mg/m
3, 600 mg/m
3 and 1200 mg/m
3 TPM), deﬁning three
subgroups. A third group of rats (15 per sex) exposed to ﬁltered
air was used as control. The objective was ‘to determine any
signiﬁcant alteration of smoke-related biological effects resulting
from menthol addition’.
33 34 At the 200 mg/m
3 smoke concen-
tration, cotinine levels were lower among the menthol group
(118.6 (SD 621.6) ng/ml vs 144.1 (SD 620.1) ng/ml; p#0.05).
Authors interpreted this ﬁnding as ‘apparently incidental’.
33 34
The ﬁnal conclusion was that ‘The results of this 13-week
inhalation study of mentholated tobacco smoke indicate that
the addition of menthol to cigarettes does not signiﬁcantly alter
the pattern, incidence, severity or reversibility of any of the
effects attributable to smoke exposure in rats’.
33 34
Menthol and cell permeability
Study published in the open literature
A study published in 1983 partially funded by the Swedish
Tobacco Company
35 36 analysed the toxicity of menthol using
four different in vitro systems: trachea from chicken embryos,
ascites sarcoma BP8 cells, isolated hamster brown adipocytes
and rat liver mitochondria. In the mitochondrial model, menthol
was found to cause an increase in the state four respiratory rate
and osmotic swelling, indicating a leakage of the mitochondrial
membrane. The authors suggested that one effect of menthol
could be a deterioration of biological membranes.
35 36
DISCUSSION
This paper assessed tobacco industry research on potential direct
disease-inducing effects of menthol and mentholated cigarettes.
In the studies presented here, menthol is described as an additive
that does not accumulate in people smoking up to 21 cigarettes,
that is metabolised in the liver and that is mostly excreted in
urine as glucuronide.
13e15 Menthol’s effect on levels of biomarkers
of smoke exposure is less well examined; however, one in-house
study concluded menthol does not modify them.
33 34 Menthol
was also suggested to degrade biological membranes
35 36 and to
produce more severe histopathological changes in the upper
airways when compared to non-menthol cigarettes.
26 Menthol
itself is presented as a non-carcinogenic substance. There is
a lack of information on other long-term effects.
Results from the 1978 BAT’s Group Research and Develop-
ment Center study on menthol’s pharmacokinetics on humans
15
were not reproduced in an article published in 1999.
37 While the
BAT study found that 80e90% of the menthol was eliminated
during the smoking period or within 4 hours post-exposure,
15
Gelal et al reported that the recovery of administered menthol as
the glucuronide averaged only 45.6% and 56.6% in 24-hour urine
samples.
37 In the BAT study menthol was absorbed through
smoking mentholated cigarettes,
15 while in Gelal’s study,
menthol was orally administered.
37
Regarding RJ Reynold’s large TRD-ATS-017 study, the
company decided to present results at a public scientiﬁc meeting
indicating that ‘There were no effects from addition of menthol
to test or reference cigarettes’,
25 when the company’s internal
pathology analysis contradicted this statement.
26 There was an
attempt to discard this conclusion internally as well,
23 a position
contested inside the company.
27 In any event, the histopatho-
logical results suggesting an adverse effect of menthol do not
appear to have been published. We did not ﬁnd evidence that
RJ Reynolds did additional research designed to resolve the
internal controversy about whether or not menthol had adverse
histopathological effects.
Most of the information on menthol’s direct disease-inducing
effects found among the tobacco industry documents comes
from summaries that the companies prepared of the open
biomedical literature, not from studies carried out by the
companies themselves. The presence of several scientiﬁc litera-
ture reviews developed for internal purposes (such as training)
seem to indicate that the industry in most cases considered this
information to be sufﬁcient to conclude that menthol did not
have any direct disease-inducing effects. Evidence that contra-
dicted this conclusion was downplayed. The companies did not
seem interested in following up on the positive ﬁndings in the
literature with their own studies, except for one study designed
to counter the conclusion that menthol was pyrolised into the
carcinogen benzo(a)pyrene.
16e18
Overall, menthol’s main health effects seem to be indirect. For
example, a 2010 paper that examined differences between self-
reported health characteristics for menthol and non-menthol
smokers using data from the 2005 National Health Interview
Survey
38 found that a larger proportion of current menthol
smokers reported having asthma and that former menthol
smokers reported a higher proportion of emergency room visits
due to asthma. The authors suggested that ‘perhaps the ‘cooling’
and ‘soothing’ effects of menthol allow smokers to engage longer
in smoking behaviours that over an extended period of time may
produce asthma-related symptoms that account emergency
room visits’.
38 This study also found that the mean number of
cigarettes smoked per day was borderline signiﬁcantly lower for
menthol smokers when compared to non-menthol smokers
controlling for sex, age and race in a multivariate analysis (OR:
0.99; 95% CI 0.98 to 1.00).
38 In contrast, another analysis of the
same dataset that stratiﬁed on race/ethnicity (African American,
Hispanic and white) and gender, controlling for age, income and
education, did not ﬁnd a signiﬁcant difference in the number of
cigarettes smoked per day between menthol and non-menthol
smokers within each ethnic group.
39
Evidence from internal tobacco documents research shows
that menthol interacts directly with nicotine,
40 affecting nico-
tine delivery
41 and that addition of menthol to cigarettes has
been used to reduce smokers’ concerns about the health
effects of cigarettes
42 and to attract and retain new, younger
smokers.
43 44 Menthol also reduces the negative sensory char-
acteristics associated with smoking
45 and may encourage
experimenters who ﬁnd non-mentholated cigarettes too harsh to
progress to regular smoking rather than quitting, and may
What is already known about this topic
Menthol is an important additive in most tobacco products and is
an identifying characteristic of many brands, yet there has been
little research into its direct disease-inducing effects.
What this study adds
Despite its importance and the widespread use of menthol as an
additive in tobacco products, the available industry documents
suggest that tobacco companies conducted little research on the
potential disease-inducing effects of menthol and did not pursue
studies that suggested adverse effects.
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Research paperinhibit the desire to quit among established menthol smokers
who have become accustomed to the taste and sensation of
menthol cigarettes.
46 Nevertheless, in the documents located,
the tobacco industry has avoided integrating this information
when discussing the disease-inducing effects of menthol.
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